DAbbrunzo I, Procida G, Perissutti B
Pharmaceutics. 2024; 16(1).
PMID: 38258039
PMC: 10821272.
DOI: 10.3390/pharmaceutics16010027.
Ma Y, Chen C, Chung L, Yen C, Juan Y, Lin R
Vet Sci. 2022; 9(7).
PMID: 35878385
PMC: 9316369.
DOI: 10.3390/vetsci9070368.
Paulino E, de Lima M, Lifsitch Vicosa A, da Silva C, Salomon C, Real D
Front Public Health. 2022; 10:848633.
PMID: 35692307
PMC: 9184718.
DOI: 10.3389/fpubh.2022.848633.
Devogelaer J, Charpentier M, Tijink A, Dupray V, Coquerel G, Johnston K
Cryst Growth Des. 2021; 21(6):3428-3437.
PMID: 34276256
PMC: 8276530.
DOI: 10.1021/acs.cgd.1c00211.
Tsiouris V, Giannenas I, Bonos E, Papadopoulos E, Stylianaki I, Sidiropoulou E
Pathogens. 2021; 10(5).
PMID: 33926144
PMC: 8147050.
DOI: 10.3390/pathogens10050524.
In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium.
Kovac J, Vargas M, Keiser J
Parasit Vectors. 2017; 10(1):365.
PMID: 28764732
PMC: 5540299.
DOI: 10.1186/s13071-017-2293-3.
Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy.
Bustinduy A, Waterhouse D, de Sousa-Figueiredo J, Roberts S, Atuhaire A, van Dam G
mBio. 2016; 7(4).
PMID: 27507822
PMC: 4992966.
DOI: 10.1128/mBio.00227-16.
Inhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to Praziquantel.
Kasinathan R, Sharma L, Cunningham C, Webb T, Greenberg R
PLoS Negl Trop Dis. 2014; 8(10):e3265.
PMID: 25330312
PMC: 4199547.
DOI: 10.1371/journal.pntd.0003265.
Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni.
Meister I, Ingram-Sieber K, Cowan N, Todd M, Robertson M, Meli C
Antimicrob Agents Chemother. 2014; 58(9):5466-72.
PMID: 24982093
PMC: 4135865.
DOI: 10.1128/AAC.02741-14.
Metabolic profiling of praziquantel enantiomers.
Wang H, Fang Z, Zheng Y, Zhou K, Hu C, Krausz K
Biochem Pharmacol. 2014; 90(2):166-78.
PMID: 24821110
PMC: 4168258.
DOI: 10.1016/j.bcp.2014.05.001.
Design and synthesis of molecular probes for the determination of the target of the anthelmintic drug praziquantel.
Sharma L, Cupit P, Goronga T, Webb T, Cunningham C
Bioorg Med Chem Lett. 2014; 24(11):2469-72.
PMID: 24775301
PMC: 4055354.
DOI: 10.1016/j.bmcl.2014.04.014.
Orally active antischistosomal early leads identified from the open access malaria box.
Ingram-Sieber K, Cowan N, Panic G, Vargas M, Mansour N, Bickle Q
PLoS Negl Trop Dis. 2014; 8(1):e2610.
PMID: 24416463
PMC: 3886923.
DOI: 10.1371/journal.pntd.0002610.
The redox biology of schistosome parasites and applications for drug development.
Huang H, Rigouin C, Williams D
Curr Pharm Des. 2012; 18(24):3595-611.
PMID: 22607149
PMC: 3638776.
Resolution of praziquantel.
Woelfle M, Seerden J, de Gooijer J, Pouwer K, Olliaro P, Todd M
PLoS Negl Trop Dis. 2011; 5(9):e1260.
PMID: 21949890
PMC: 3176743.
DOI: 10.1371/journal.pntd.0001260.
Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity.
Lima R, Ferreira M, de Jesus Ponte Carvalho T, Fernandes B, Takayanagui O, Garcia H
Br J Clin Pharmacol. 2011; 71(4):528-35.
PMID: 21395645
PMC: 3080640.
DOI: 10.1111/j.1365-2125.2010.03874.x.
Current chemotherapy arsenal for schistosomiasis mansoni: alternatives and challenges.
Abdul-Ghani R, Loutfy N, el-Sahn A, Hassan A
Parasitol Res. 2009; 104(5):955-65.
PMID: 19255786
DOI: 10.1007/s00436-009-1371-7.
Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment.
Meyer T, Sekljic H, Fuchs S, Bothe H, Schollmeyer D, Miculka C
PLoS Negl Trop Dis. 2009; 3(1):e357.
PMID: 19159015
PMC: 2614124.
DOI: 10.1371/journal.pntd.0000357.
Time course of the effect of praziquantel on Schistosoma mansoni attachment in vitro: comparison with its effects on worm length and motility.
da Silva S, Noel F
Parasitol Res. 1995; 81(7):543-8.
PMID: 7479644
DOI: 10.1007/BF00932019.
